ROR

ncRNA information

ncRNA name

ROR

Specific or universal ncRNAs

Universal ncRNAs

Class

Long noncoding RNA

Biomarker

No

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

miR-153-3p/ABCB1

Cancer information

Cancer name

Osteosarcoma

Cancer site

Bone, Articular Cartilage

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Up

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

ROR contributed to cisplatin resistance in OS via miR-153-3p/ABCB1 , unraveling a new regulatory network of chemoresistance in cisplatin-resistant OS cells and may provide a therapeutic target for OS patients.

Tissue resource

osteosarcoma tissues and primary osteosarcoma tissues

human osteosarcoma cell lines MG63

human osteosarcoma cell lines U2OS

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

Weinan Central Hospital

Cell Bank of the Chinese Academy of Sciences

Country

China

Continent

Asia